_______________________________________________________________________________________________________________ Biomedica – to OXB. Now, having successfully rebranded and distinguished itself as a global viral vector CDMO powerhouse in cell and gene therapy, OXB is embracing its new integrated brand identity and scaling its operations to new heights. As the company proceeds to grow and prosper, it remains focused on its international expansion, particularly in the US, as it continues to be a strategic partner of choice for some of the world’ s greatest pharmaceutical and biotechnology companies.
Mark Caswell, Site Head of UK Operations at OXB, joins Manufacturing Today to dive deeper into the company’ s strategic growth and the factors driving its operations. He begins our conversation by sharing insight into the acquisition of OXB’ s two French sites back in 2024 and how they further expanded the company’ s GMP manufacturing capabilities in Europe.
“ The acquisition of these two sites was focused around supplying the European markets amidst all the Brexit changes coming into effect. Additionally, the existing expertise that these sites held in terms of other viral vectors further supported a vector-agnostic approach,” he explains.“ They’ ve also given us the unique ability to scale commercial production, unlocking continued growth and new opportunities for us in France.”
Moving on to OXB’ s US expansion, Mark shares an exciting development:“ We’ ve recently purchased a second facility in the US to further expand our commercial footprint and support our clients. A lot of our clients are based in the US, and so we wanted to address some of their concerns surrounding tariffs and being able to manufacture in their own market. The new US facility is one of the ways that we’ ve been able to give our clients some relative assurance alongside growing
42